Business Wire

Healthcare at Home Launches Sciensus Rare to Connect Emerging Biotech and Large Pharma Companies With Rare Disease Patients in Europe and Beyond

Share

Healthcare at Home today unveils a dedicated new rare disease medicines services business: Sciensus Rare.

Sciensus Rare launches with two main aims: to ensure that patients and their families have access to the rare disease medicines and care they need, and to help biotech and pharmaceutical companies safely launch and efficiently deliver vital medication, no matter where a patient lives or the regulatory governance of that country.

The business will continue to help emerging, mid-sized, and major biotech and pharmaceutical companies gain market access in Europe and beyond, expanding Healthcare at Home’s existing rare disease and orphan medicines services further geographically and by therapy area, across five main services:

- Clinical trials in the home

- Medicines access

- Bespoke supply chain management

- Patient and family support

- Outcome monitoring in the home

According to Eurostat, the market for rare disease pharmaceutical medicines services is expected to more than double in size over the next few years, growing from €1.6bn in 2018 to €3.3bn in 2025, as the number of products requiring more complex services to support them grows. Sciensus Rare aims to meet the growing demand by creating a unique, science-led approach to help pharmaceutical partners reduce time to market for innovative, high cost, new medicines in a rapidly changing marketplace, helping to eliminate unnecessary costs and inefficiencies in the drug development process.

Gareth Williams, President of Sciensus Rare, said:

“The global pandemic has accelerated the need for bespoke patient-centred services which are required for products in drug development and commercial phases as many rare disease patients can’t or won’t travel long distances to take part in clinical trials away from home.

“Our aim is to help emerging biotech firms which have a strong presence in their home market but little or no international distribution or commercial infrastructure, as well as the established pharma companies seeking access to treatment for patients with unmet needs”.

Sciensus Rare’s services build on Healthcare at Home’s three decades of experience in treating rare disease patients. In that time, the business has treated more than 52,000 patients at home, and collaborated with over 20 rare disease pharmaceutical companies and over 4,000 healthcare providers in mainland Europe. BioMarin, which specialises in developing and commercialising biopharmaceuticals for rare diseases driven by genetic causes, has been working with Healthcare at Home since 2006 and now sees a quarter of its global sales delivered through this model.

Guy Eggleton, Executive Director Sales and Marketing Operations EUMEA, at BioMarin, said:

“Sciensus Rare has tremendous potential to build on its significant experience in rare diseases to become the global expert in helping businesses like ours connect rare disease patients and healthcare providers with effective, innovative new treatments for rare conditions.”

The need to develop and provide access to safe, effective medicines is most acute in rare diseases, many of which are genetic and affect younger patients.

Williams concluded:

“The ‘one size fits all’ approach to rare and orphan managed medication services, with no clear integrator of drug development through to commercial services is now outmoded and redundant. With many new therapies coming to market from a burgeoning pharmaceutical research and development side, it is clear to us that there is a role for a different kind of bespoke managed pharmaceutical services provider that puts the needs of the patient at its heart regardless of where the therapy is in its lifecycle.”

The Sciensus Rare name will replace Healthcare at Home’s Rare Disease Medicines Service.

** ENDS **

NOTES TO EDITORS

About Sciensus Rare ( www.sciensusrare.com)
We believe in making sure every family has access to rare disease medicines and the care they need. No matter where a patient lives or the regulatory governance of that country, we can safely launch and efficiently deliver vital medication and clinical services for families that need it most.

Contact information

Joshua Vine-Lott at Aurora Healthcare Communications:
Joshua.Vine-Lott@auroracomms.com
+44 (0)7543 222 552

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Disruptive Tech Asean Comments That Semiconductor Industry in China Eyes on a New Beyond the Manufacturing Of 7nm Chips3.12.2020 11:00:00 CETPress release

Disruptive Tech Asean learnt from Li Ke from China Semiconductor Industry Association (CSIA) that an integrated circuit industry is vital for developing modern industries, and China is therefore imperative to localize chip industry supply chain and develop homegrown-core chips. Li Ke believes that China will have the ability to fully mass-produce its own 28nm chips in one or two years, as well as having a completely domestic industry chain and independent chip manufacturing capabilities. According to Gartner’s forecast at the end of 2019, the global semiconductor market would grow by 12.5% in 2020. Yet, with devastating impacts of the COVID-19 pandemic, the forecast was revised to a decline of 0.9%. According to Andrew Norwood, Research Vice President at Gartner, “COVID-19 has distorted supply chain and manufacturing operations across the world and will lead to a drastic drop in consumer and enterprise spending across most areas with a few exceptions.” The US-China trade war has also c

LivaNova and Gyrus Capital Enter into Agreement for the Purchase of Heart Valve Business3.12.2020 11:00:00 CETPress release

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, and Gyrus Capital (Gyrus), an investment firm dedicated to investments in the healthcare and sustainability sectors, today announced they have entered into an agreement whereby entities funded and controlled by Gyrus will acquire the LivaNova heart valve (HV) business. The LivaNova Board of Directors unanimously approved the divestiture, which it believes will enable the Company to sharpen its focus within its primary platforms, neuromodulation and cardiovascular, and to dedicate increased resources toward executing its promising pipeline opportunities. Once the transaction is complete, Gyrus intends to focus management attention and investment on the HV business to position it to become a leading player in the surgical heart valve market globally, translating into even greater opportunities for employees, customers and patients. This press release features multimedia. View the full release here: ht

Telefonica UK (O2) and IDEMIA Working to Securely Connect 23 Million Homes in the UK With Smart Meters By 20253.12.2020 10:30:00 CETPress release

O2 in partnership with IDEMIA, the global leader in Augmented Identity, has today supplied secure connectivity to over 4 million UK homes with a second generation Smart Meter. The rollout will continue into the future, supporting the UK government program to deploy Smart Meters for all UK households and small businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201203005370/en/ (Photo: Business Wire) As part of the transition to a flexible energy market that requires a low carbon economy and sustainable consumption habits, smart meters give consumers near real-time information on energy helping them to take control of their energy usage and bring an end to estimated billing. Smart meters come with in-home displays to enable consumers to have a better understanding of their energy usage. Against that backdrop, customers using the latest generation of smart meters are reporting an average saving of around 10% per month.

Measuring What Matters: A New Approach to Assessing Sovereign Climate Risk3.12.2020 09:23:00 CETPress release

Moody’s affiliate Four Twenty Seven today released a report analyzing the future exposure of the global population, the economy, and agriculture to a range of climate hazards, exploring both global trends and findings by country. Leveraging new analytics developed by Four Twenty Seven, the report assesses exposure to floods, heat stress, hurricanes and typhoons, rising sea levels, wildfires, and water stress and is based on the only known global dataset matching physical climate risk exposure to population location, GDP Purchasing Power Parity (PPP), and agricultural areas within countries. “This novel dataset provides a detailed view of the exposure of key human and economic assets around the world. Understanding exposure is critical for investors and credit institutions to price climate risk, but also to help direct finance flows towards adaptation and resilience where they’re most needed,” says Emilie Mazzacurati, Global Head of Moody’s Climate Solutions in Moody’s ESG Solutions Gro

PMI Commits to Disability Inclusion by Joining The Valuable 5003.12.2020 09:05:00 CETPress release

Philip Morris International Inc.(PMI) (NYSE: PM) today announced that CEO André Calantzopoulos has joined The Valuable 500—a global movement putting disability inclusion on the business leadership agenda. Signing on to this initiative marks another significant step in PMI’s journey of advancing inclusion and diversity in the workplace. André Calantzopoulos said: “Businesses with a global operating footprint, such as PMI, can make a meaningful impact by ensuring that everyone—including individuals with a disability—can prosper in the workplace. By signing The Valuable 500, I am proud to join forces with a host of other CEOs who are challenging their organizations and the business world to broaden the focus of their inclusion and diversity efforts, and to help create a more inclusive world for the 1.3 billion people with disabilities. This is the right thing to do as part of our broader work to create a more equitable society. And it is also the smart thing to do, allowing PMI to tap int

Siemens Smart Infrastructure Chooses AWS as Its Preferred Cloud Provider for SAP Environments3.12.2020 09:01:00 CETPress release

Today, Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), announced that Siemens Smart Infrastructure, a business of the Siemens AG group focusing on energy distribution and intelligent buildings, is moving its SAP infrastructure to AWS. The business will migrate over 20 Enterprise Resource Planning (ERP) and Supply Chain Management (SCM) systems,based on SAP HANA, to AWS before the end of 2021. These systems support business-critical processes in areas such as manufacturing, operations, and sales across different business units including Building Products, Electrical Products, Digital Grid, and Distribution Systems. Moving these workloads to AWS will enable Siemens Smart Infrastructure to significantly shorten hardware refresh cycles, increase agility to test and deploy new systems, and provide the foundation for the company’s future transformation using SAP S/4HANA technology. This is the first migration of production-scale SAP systems to the cloud across the Siemens AG

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom